Breakfast brief: Weight management probiotic support: A new sustainable stress free approach (Linpharma Bioactives)

Linpharma Bioactives would like to see YOU at their breakfast brief session as they discuss their patented probiotics for weight management.

The non-meal supplements market for weight management will hit $2 billion by 2025 while probiotics account for nearly 60% of the gastrointestinal market (source: Nutrition Business Journal). Linpharma Bioactives’ patented and custom selected probiotic microbes such as JBD 301 help eliminate dietary fat, which normally become free fatty acids (FFAs) and glycerides in the small intestine. JBD 301 is fundamentally different in its mechanism of action from any current FDA-approved prescription drug. It is not a drug, and it produces healthful benefits without the oily, loose stools, leakage, abdominal pain, or other side effects commonly associated with weight-loss medications.

Attendees will learn:

• Benefits of probiotics JBD 301, 302, 305 and 309
• Results of clinical animal and human trials
• Scientific design
• Application benefits

Speakers:

• Volker Gallichio, MBA, Chief business & market development officer, Linpharma Bioactives
• Annette Zehrer, Ph.D., senior scientist, preclinical, clinical research & development, Linpharma Bioactives

This brief is an invite-only event. If you are interested in attending, please reach out to Shilo Lusson at shilo.lusson.us@informa.com.